Autologous stem cell transfusions on multiple days in patients with multiple myeloma-Does it matter?

Hematol Oncol. 2019 Dec;37(5):649-651. doi: 10.1002/hon.2673. Epub 2019 Sep 13.

Authors

Sebastian Moser¹, Ulrike Bacher², Barbara Jeker¹, Behrouz Mansouri Taleghani², Daniel Betticher³, Axel Ruefer⁴, Thomas Egger⁵, Urban Novak¹, Thomas Pabst¹

Affiliations

¹ Department of Medical Oncology, Inselspital University Hospital and University of Bern, Bern, Switzerland.
² Department of Hematology and Central Hematology Laboratory, Inselspital University Hospital and University of Bern, Bern, Switzerland.
³ Department of Oncology, Kantonsspital, Fribourg, Switzerland.
⁴ Department of Hematology, Kantonsspital, Lucerne, Switzerland.
⁵ Department of Oncology, Bürgerspital Solothurn, Solothurn, Switzerland.

PMID: 31483507
DOI: 10.1002/hon.2673

No abstract available

Publication types

Letter

MeSH terms

Hematopoietic Stem Cell Transplantation* / adverse effects
Hematopoietic Stem Cell Transplantation* / methods
Humans
Multiple Myeloma / diagnosis
Multiple Myeloma / mortality
Multiple Myeloma / therapy*
Prognosis
Time Factors
Transplantation, Autologous
Treatment Outcome

Grants and funding

38-167/Swiss Cancer League